Asimov is a Synthetic Genomics & Data Storage company founded in 2017 and based in Boston, United States. It has raised $209M in total funding, most recently a Series B in 2023.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Jan 5, 2023 | Series B | $175M | — | CPP Investments |
No articles ingested yet for Asimov. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
A computer-aided design platform for engineering complex genetic systems, intended to bring the predictability and tooling of electronic design automation to biology. Kernel lets scientists design, simulate, and refine genetic constructs and regulatory circuits before building them, improving the precision and reliability of engineered cells. It underpins Asimov's design services and is used alongside the company's engineered cell lines to develop production systems for biologics and advanced therapies.
A family of engineered mammalian cell lines and production systems for manufacturing therapeutics, including the CHO Edge System for biologics, LV and AAV Edge Systems for viral-vector-based cell and gene therapies, and an RNA Edge System. Each pairs Asimov's optimized, genetically engineered cell lines with design tools and protocols to improve yield, quality, and scalability of therapeutic manufacturing. The systems are licensed to pharma, biotech, and contract manufacturing partners developing advanced therapies.
1 patent on file, but none with both an extractable figure and an abstract on Google Patents yet.